Compare Amgen, Inc. (AMGN) vs Rocket Lab USA Inc (RKLB) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amgen, Inc. vs Rocket Lab USA Inc — how do they compare? Amgen, Inc. trades at $363.66 (market cap $196.12B), while Rocket Lab USA Inc trades at $80.3 (market cap $50.64B). The key difference: Amgen, Inc. is far larger — about 3.9× Rocket Lab USA Inc's market cap, and Amgen, Inc. pays a 2.77% dividend while Rocket Lab USA Inc pays none. Which is the better fit depends on your goals.
| AMGN | RKLB | |
|---|---|---|
Market Cap | $196.12B | $50.64B |
Sector | Health | Technology |
52-Week High | $388.16 | $150.23 |
52-Week Low | $271.18 | $39.03 |
Enterprise Value | $241.41B | $49.39B |
Dividend Yield | 2.77% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $363.39, down slightly by 0.06% today, with a bullish technical signal from moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $5.15 versus $4.77 expected. Revenue grew to $36.75B in 2025, with a net income margin of 20.96%. Recent news includes a favorable court ruling blocking a price cap on Enbrel in Colorado, but regulatory challenges persist for Tavneos in Europe.
The outlook remains positive due to consistent earnings beats and a diversified product portfolio, though risks include regulatory setbacks and competitive pressures. Analyst consensus is bullish with a 57.9% buy rating and a price target of $357.38, slightly below the current price, indicating potential for stability with upside from pipeline developments.
Rocket Lab (RKLB) trades at $81.04, down 1.83% amid broader space sector weakness. The stock shows bearish technical signals with support at $77-$81 levels, while fundamentals reveal strong revenue growth ($602M in 2025) but persistent losses (-$198M net income). Recent news highlights the $8B Iridium acquisition and innovative 'Hungry Hippo' technology, positioning the company for long-term growth in the expanding space economy.
Analyst consensus remains bullish with a $119.10 price target (75% buy ratings), though profitability challenges and high valuations (P/S 66.26) present near-term risks. The company's expansion into satellite communications and defense contracts provides growth catalysts, but investors face volatility from sector-wide valuation concerns and execution risks on major acquisitions.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About Rocket Lab USA Inc
Rocket Lab USA, Inc. is an aerospace manufacturer and small-satellite launch service provider. The company specializes in developing rockets for orbital launch, including its flagship *Electron* vehicle, and is developing the next-generation, reusable *Neutron* rocket. Beyond launch services, Rocket Lab also offers satellite design, manufacturing, and spacecraft component solutions, positioning itself as an end-to-end provider for the space industry.
Read more on RKLB →
